Follicular Lymphoma (FL)

  • Method:
  • Anticoagulant:
  • Recommendation:
  • Method:
    Cytomorphology
  • Anticoagulant:
    EDTA
  • Recommendation:
    obligatory
  • Method:
    Immunophenotyping
  • Anticoagulant:
    EDTA or Heparin
  • Recommendation:
    obligatory
  • Method:
    Chromosome analysis
  • Anticoagulant:
    Heparin
  • Recommendation:
    facultative
  • Method:
    FISH
  • Anticoagulant:
    EDTA or Heparin
  • Recommendation:
    obligatory
  • Method:
    Molecular genetics
  • Anticoagulant:
    EDTA or Heparin
  • Recommendation:
    facultative

Based on the current guidelines and the current state of research, there are different diagnostic recommendations for patients with follicular lymphoma. We have summarized the most important information on classification and diagnostic methods for MLL. In addition, we provide further links on the prognosis and therapy of follicular lymphoma, so that you can inform yourself in more detail.

Follicular Lymphoma: Classification

According to the WHO 2022 classification, follicular lymphoma is a mature B-cell neoplasm and accounts for 10-20% of all lymphomas, with the highest rates reported in Western Europe and the United States and the lowest in Eastern Europe and Asia. It arises from the B cells of the germinal center of the lymphoid follicle (centrocytes & centroblasts). Currently, the following variant forms are distinguished (WHO 2022):

Table 1: Follicular Lymphoma WHO classification (WHO 2022)

Variant forms of follicular lymphoma

 

 

Classic FL (cFL)

 

IGH::BCL2/t(14;18) positive

Follicular large B-cell lymphoma (FLBL)

 

Largely equals FL grade 3B

FL with uncommon features (uFL)

FL with blastoid/large centrocytes

Variant immunophenotypic and genotypic characteristics, inferior survival, need to be distinguished from LBCL-IRF4

FL with diffuse growth pattern

Associated with CD23 expression, absence of BCL2 translocation, frequent STAT6 mutations along with 1p36 deletion or TNFRS14 mutation

In situ follicular B-cell neoplasm (ISFN)

 

Infiltration of single germinal centers with IGH::BCL2 t(14;18)-positive cells; low potential for progression

Duodenal-type FL

 

IGH::BCL2/t(14;18) positive, mostly confined to intestinal mucosa, low risk of progression

Paediatric-type FL

 

No BCL2 translocation

Diffuse variant of follicular lymphoma (dFL)

 

No IGH::BCL2/t(14;18) translocation, similar expression profile as typical FL

The WHO 2017 histologic classification of follicular lymphomas based on their centroblast content into grades 1, 2, 3A, and 3B, with grades 1-3A belonging to indolent lymphomas and grade 3B to aggressive lymphomas (Swerdlow et al. 2017) is now no longer mandatory (WHO 2022). The progression of lymphoma is assessed using the Ann Arbor classification. The grading here is into stages I-IV (Onkopedia guideline follicular lymphoma 2023).

Follicular Lymphoma: Diagnostic methods

Follicular Lymphoma: Prognosis

The Follicular Lymphoma International Prognostic Index (FLIPI) and the genetically enhanced m7-FLIPI are used for risk assessment of follicular lymphoma (Solal-Celigny et al. 2004, Pastore et al. 2015).

Follicular Lymphoma: Recommendation

Important notes on the examination material

The diagnosis of follicular lymphoma should be made on the basis of surgical lymph node extirpation, if possible, and also from peripheral blood and bone marrow in advance or in parallel. For initial screening in inaccessible, e.g. retroperitoneal lymph nodes, a lymph node biopsy can be performed alternatively. Fine-needle aspiration (cytology) alone is not sufficient because of possible focal heterogeneity of lymphoma tissue and the possible need for further immunologic and molecular genetic testing.
If lymphoma cells are detected in peripheral blood, the diagnosis can initially be made with a high degree of confidence without bone marrow biopsy or lymph node sampling. If enlarged lymph nodes are clinically prominent, a lymph node should be removed and histologically and immunohistologically processed. Based on these findings, an extended material sampling, e.g. of bone marrow, is then useful in individual cases and if clinically relevant.

Follicular Lymphoma: Therapy

Reviews of treatment strategies are available in the Onkopedia Follicular Lymphoma Guideline, from Jacobsen (Jacobsen 2022) and from Gordon et al. (Gordon et al. 2023).

Status: August 2023

You may also be interested in

Career

As a rapidly growing, innovative medical laboratory, we are always looking for bright minds to help us bring new and more effective therapies to patients around the world.

Learn more

Services

Do you have questions about sample submission, analyses performed or findings? Here you will find contact details, contact persons and our most frequently asked questions (FAQs).

Learn more

Quality management

We have been certified according to national and international standards since 2009 and have successfully maintained these accreditations.

Learn more